Filing Flows › Scribe Therapeutics (SCTX) › Q2 2026
Scribe Therapeutics (SCTX) Q2 2026 earnings results (second quarter 2026)
10-Q filed Sep 2, 2026
Scribe Therapeutics (SCTX) reported revenue of $1.9M for the second quarter 2026 (Q2 2026), -61% from a year earlier. Operating margin was -489.8%, net loss $6.5M (337.7% of revenue).
Scribe Therapeutics, Q2 2026: revenue $1.9M (-61% year over year), operating margin -489.8%, net loss $6.5M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $1.9M | — | -61% |
| Operating profit | −$9.4M | — | — |
| Net earnings | −$6.5M | — | — |
What changed
Revenue was $1.9M in Q2 2026, down 61% year over year.
Operating costs exceeded revenue by $9.4M, an operating margin of -489.8%. Total costs fell 32% while revenue fell 61%. The quarter ended with a net loss of $6.5M. Non-operating items added $3.1M, -50% of pre-tax earnings, so the bottom line overstates operating performance.
Questions
What was Scribe Therapeutics' revenue in the second quarter 2026?
Scribe Therapeutics (SCTX) reported revenue of $1.9M for the second quarter 2026 (Q2 2026), -61% from a year earlier.
Was Scribe Therapeutics profitable in the second quarter 2026?
Operating loss was $9.4M (-489.8% of revenue) and net loss $6.5M.